Triple Negative Breast Neoplasms

This refers to certain types of breast cancer. It's called 'triple negative' because the cancer cells do not have receptors for estrogen, progesterone, or the HER2 protein. This type of cancer can be more challenging to treat.

Condition

What people with Triple Negative Breast Neoplasms report

Every report comes from a Lived member, sent anonymously.

Have you tried Keytruda (Pembrolizumab) for Triple Negative Breast Neoplasms?

NameHow it went

About Triple Negative Breast Neoplasms

What It Is

Triple-negative breast cancer (TNBC) is a type of invasive breast cancer defined by what its cells lack. Most breast cancers are fueled in part by the hormones estrogen or progesterone, or by too much of a growth-signaling protein called HER2. TNBC cells test negative for all three: they have no estrogen or progesterone receptors and do not make excess HER2. That result matters because it rules out two of the most widely used breast cancer treatments. Hormone-blocking pills and HER2-targeted drugs work by acting on those features, so they do not help TNBC. Treatment relies instead on chemotherapy and a growing set of newer medicines. TNBC makes up roughly 10% to 15% of breast cancers. Compared with other invasive breast cancers, it tends to grow faster, is more often found at a later stage and is more likely to come back after treatment. It also often responds well to chemotherapy, and many people treated for early-stage TNBC do very well.

Causes & Risk Factors

The cause of TNBC is not known, and no single habit or exposure explains why one person develops it. Its general risk factors are largely the same as for other breast cancers, including older age, family history, alcohol use and excess weight. Certain groups are more likely to have this particular type. TNBC is more often diagnosed in younger women and those who have not reached menopause, and it is more common, and tends to appear at a younger age, in Black women than in White women. It is also more common in people born with a harmful change in the BRCA1 gene, and to a lesser degree BRCA2. These genes normally help repair damaged DNA, and an inherited change raises the lifetime risk of breast and ovarian cancer. Belonging to one of these groups raises the odds; it does not mean someone will develop TNBC.

How It's Diagnosed

TNBC is found the same way as other breast cancers: through a lump or other change someone notices, or on a screening mammogram. Imaging such as a mammogram, ultrasound or breast MRI shows the area of concern, and a biopsy (removing a small sample of tissue with a needle or in surgery) confirms whether it is cancer. The triple-negative label comes from lab tests on that biopsy sample. A pathologist checks the cancer cells for estrogen receptors (ER), progesterone receptors (PR) and HER2. When all three are negative, the cancer is classified as triple negative. The pathology report also describes the tumor's grade, which reflects how abnormal the cells look and how quickly they are likely to grow. Further tests then establish the stage, meaning how far the cancer has spread. This can include examining nearby lymph nodes and, in some cases, CT or PET scans of the body. Genetic testing for inherited BRCA changes is recommended for everyone newly diagnosed with breast cancer at 65 or younger and for some older people. For TNBC the result can directly change treatment, and it also matters for relatives who may share the same gene change.

Treatment Options

Treatment depends mainly on the stage. For cancer that has not spread beyond the breast and nearby lymph nodes (stages I to III), the goal is cure. Surgery removes the tumor, either by lumpectomy (removing the cancer and a margin of healthy tissue) or mastectomy (removing the breast), along with checking the lymph nodes. Radiation often follows a lumpectomy and may be advised after mastectomy when the tumor was large or the nodes contained cancer. Chemotherapy is the main drug treatment. For small tumors it may come after surgery. For larger tumors or cancer in the lymph nodes, it is often given first, which can shrink the cancer before surgery and shows how well it responds. For high-risk early TNBC, the immunotherapy drug pembrolizumab (Keytruda) is commonly added to this pre-surgery chemotherapy and then continued on its own afterward. It helps the immune system recognize cancer cells and lowers the chance of the cancer returning. Its trade-off is that the immune system can also attack healthy organs, such as the thyroid, lungs, bowel or liver, sometimes seriously, so new symptoms during or after treatment need prompt reporting. If no cancer is left in the tissue removed at surgery, the outlook is especially good. If some cancer remains, the team may recommend more treatment afterward, such as capecitabine, a chemotherapy pill, or for people with an inherited BRCA change, a year of olaparib (Lynparza). Olaparib is a PARP inhibitor, a pill that targets the weakened DNA repair in BRCA-related cancers, and it has helped some people live longer. When TNBC has spread to distant parts of the body (stage IV), treatment aims to control the cancer, extend life and ease symptoms rather than cure it. Choices depend on whether the cancer makes a protein called PD-L1, which predicts benefit from immunotherapy, and on prior treatment and gene changes. Options include sacituzumab govitecan (Trodelvy), an antibody that carries chemotherapy directly to cancer cells, given with pembrolizumab when the cancer is PD-L1 positive; other chemotherapy; and PARP inhibitors for people with BRCA changes. Because TNBC has fewer targeted options than other breast cancers, clinical trials are a reasonable option to consider at any stage.

What to Expect

Treatment for early-stage TNBC usually takes many months. Chemotherapy, often with immunotherapy, commonly runs for several months before surgery, followed by recovery from surgery, possibly several weeks of radiation, and sometimes further treatment afterward. Fatigue, hair loss, nausea and a higher risk of infection are common during chemotherapy, and many people adjust work and family routines during this period. Most of these effects ease after treatment ends, although some, such as numbness in the hands and feet or long-term thyroid changes after immunotherapy, can last. Outlook depends most on the stage at diagnosis. Based on women diagnosed between 2015 and 2021, about 92% of those whose cancer was confined to the breast were alive five years later relative to the general population, compared with about 67% when it had spread to nearby lymph nodes or tissues and about 15% when it had spread to distant organs. These figures predate some newer treatments and cannot predict any one person's course. After treatment, follow-up visits, physical exams and yearly mammograms continue for years. Emotional support, practical help and, for those with BRCA changes, planning for their own and relatives' future cancer risk are an ordinary part of care.

When to Seek Help

See a clinician promptly about a new breast lump, swelling of part of a breast, skin dimpling or thickening, a nipple turning inward, nipple discharge that is not breast milk, or swollen lymph nodes under the arm or near the collarbone. Most breast changes are not cancer, but they should be checked. After treatment, tell your care team about any new lump in the breast, chest wall or armpit, or other new symptoms that persist, rather than waiting for the next scheduled visit. Tests are usually done when symptoms suggest the cancer may have returned. During chemotherapy, call your care team right away for a fever of 100.5°F (38°C) or higher, chills, or other signs of infection, because infection while white blood cell counts are low can become life threatening quickly. If you have had immunotherapy, call right away about diarrhea or severe belly pain, a new or worsening cough or shortness of breath, or yellowing of the skin or eyes, even months after the last dose, since these can signal immune side effects that need prompt treatment.

Questions to Ask Your Doctor

  1. 1.What is the stage and grade of my cancer, and what is the goal of treatment?
  2. 2.Should I have chemotherapy before surgery, and would adding immunotherapy make sense for me?
  3. 3.Have I had genetic testing for BRCA and related genes, and how would the results change my treatment or affect my family?
  4. 4.Which side effects should I report right away, and who do I call after hours?
  5. 5.Are there clinical trials I should consider now or if the cancer comes back?

Last reviewed • Oct 2026

Educational content, not medical advice.